ClinicalTrials.gg
SuspendedNCT06761677Updated Feb 5, 2026

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

A Phase 1/2 interventional study of Brincidofovir in Relapsed or Refractory Lymphoma Including ENKL, sponsored by SymBio Pharmaceuticals. Suspended at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Primary conditionLymphoma, T-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, T-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's title name Lymphoma, T-Cell.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by SymBio Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Why this study was suspended
Due to challenges in recruiting eligible patients under the protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose limiting toxicity (DLT), maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), pharmacokinetics (PK), and preliminary efficacy of BCV in patients with relapsed or refractory lymphoma and to assess the efficacy and safety of Brincidofovir (SyB V-1901, BCV) in patients with relapsed or refractory Extranodal Natural Killer/T-cell Lymphoma (ENKL).

This study consists of 2 parts and will enroll a total (maximum) of 43 male and female participants who meet the eligibility criteria (Phase 1b part: Up to 18 participants [3 to 6 participants in each of the 3 cohorts], Phase 2 part: 25 participants).

02

Conditions studied

  • Relapsed or Refractory Lymphoma Including ENKL

Keywords

  • SyB V-1901
  • BCV
  • Relapsed or refractory Lymphoma
  • Extranodal Natural Killer/T-cell Lymphoma
  • ENKL
  • EBV-positive nodal T- and NK-cell lymphoma
  • EBV + nTNKCL
  • nodal T-follicular helper cell lymphoma
  • nTFHcL
  • angioimmunoblastic T-cell lymphoma
  • AITL
  • peripheral T-cell lymphoma not otherwise specified
  • PTCL-NOS
  • anaplastic large cell lymphoma
  • ALCL
  • diffuse large B-cell lymphoma
  • DLBC
  • DLBCL-NOS
  • adult T-Cell Leukemia Lymphoma
  • ATLL
03

In context

Lymphoma, T-Cell Reclassified

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

This study's planned enrollment of 43 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

SymBio Pharmaceuticals is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are histopathologically diagnosed with ENKL based on the World Health Organization (WHO) Classification of Malignant Lymphoma 5th Edition (WHO-HAEM5) (can be enrolled in the Phase 1b part and the Phase 2 part) or patients diagnosed with EBV-positive nodal T- and NK-cell lymphoma (EBV + nTNKCL), nodal T-follicular helper cell lymphoma (nTFHcL) (including angioimmunoblastic T-cell lymphoma (AITL) as defined in the WHO Classification, 4th Edition), peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma (DLBCL) (e.g., DLBCL, NOS), or adult T-Cell Leukemia Lymphoma (ATLL) (can only be enrolled in the Phase 1b part)
  • Patients with lymphoma and previously treated with systemic chemotherapy (history of multidrug chemotherapy including L-asparaginase such as SMILE therapy for ENKL is mandatory) who are ineligible for other systemic therapies
  • Patients with the following (ECOG) Performance Status (PS):
  • Phase 1b part: 0-1
  • Phase 2 part: 0-2

Exclusion criteria

Exclusion Criteria:

  • Patients with another active malignant tumor requiring treatment
  • Patients with Grade 2 or higher diarrhea (increase of 4 or more bowel movements per day compared to usual number of bowel movements) within 7 days prior to starting the first dose of BCV
  • (GVHD) patients requiring agents
  • Patients with a history of Cidofovir intolerance
  • Patients with a history of being diagnosed with cirrhosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Brincidofovir twice weekly (BIW) via intravenous infusion

    Drug: Brincidofovir

Interventions

  • Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).

    Also known as: SyB V-1901, BCV

06

What researchers measure

Primary outcomes

  1. Phase 1b part (Dose Escalation Part)

    Adverse events (AEs) that meet the protocol-defined DLT criteria in Cycle 1 and the number of participants that developed these AEs

    Time frame: 28 days

  2. Phase 2 part (Expansion Part)

    Best Overall Response as of end of treatment

    Time frame: 7 months

07

Study locations

8 sites
  • Queen Mary Hospital
    Hong Kong, China
  • Tokyo Metropolitan Komagome Hospital
    Bunkyō City, Japan
  • National Cancer Center Hospital
    Chūōku, Japan
  • Cancer Institute Hospital Of JFCR
    Kōtoku, Japan
  • Kyoto University Hospital
    Kyoto, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Mie University Hospital
    Tsu, Japan
  • National Cancer Centre Singapore
    Singapore, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 7, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Oct 23, 2027
CompletionEst.
May 8, 2029
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761677
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jun 9, 2025
Primary completion
Oct 23, 2027 (estimated)
Completion
May 8, 2029 (estimated)
Last update
Feb 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion